Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Isoniazid
Drug ID BADD_D01204
Description Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Indications and Usage For the treatment of all forms of tuberculosis in which organisms are susceptible.
Marketing Status approved; investigational
ATC Code J04AC01
DrugBank ID DB00951
KEGG ID D00346
MeSH ID D007538
PubChem ID 3767
TTD Drug ID D09XQF
NDC Product Code 60687-553; 0555-0071; 71610-395; 83112-071; 50090-0410; 63187-978; 0555-0066; 68788-9405; 71610-108; 12785-0003; 50090-0370; 70518-0096; 70518-2576; 43063-463; 62135-550; 0781-3056; 12785-0002; 66639-914; 51079-083; 43367-0100; 71052-611; 46287-009; 71335-0275; 53002-2920
UNII V83O1VOZ8L
Synonyms Isoniazid | Isonicotinic Acid Hydrazide | Hydrazide, Isonicotinic Acid | Phthivazide | Phthivazid | Isonicotinic Acid Vanillylidenehydrazide | Acid Vanillylidenehydrazide, Isonicotinic | Vanillylidenehydrazide, Isonicotinic Acid | Ftivazide | Tubazide | Isonex
Chemical Information
Molecular Formula C6H7N3O
CAS Registry Number 54-85-3
SMILES C1=CN=CC=C1C(=O)NN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood uric acid13.02.04.003--Not Available
Body temperature increased13.15.01.001--Not Available
Breast enlargement21.05.04.001--Not Available
Cachexia16.32.03.011; 14.03.02.001; 08.01.01.0090.002780%Not Available
Cardiac arrest02.03.04.0010.006949%
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.004170%Not Available
Cardiomegaly02.04.02.0010.002780%Not Available
Cerebellar ataxia17.02.02.013; 08.01.02.0060.002780%Not Available
Chills15.05.03.016; 08.01.09.0010.013899%
Cholestasis09.01.01.0010.009729%Not Available
Chromaturia20.02.01.0020.015289%
Coagulopathy01.01.02.0010.004170%Not Available
Coma17.02.09.0010.026408%Not Available
Coma hepatic17.02.09.002; 09.01.03.0050.008339%Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Coordination abnormal17.02.02.004--Not Available
Cough22.02.03.0010.013899%
Dehydration14.05.05.0010.006949%
Delirium19.13.02.0010.006949%
Demyelination17.16.02.0010.002780%Not Available
Depressed level of consciousness17.02.04.0020.004170%
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.0150.005560%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene